Article
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake
Registro en:
ESPADA, Caroline Ricce et al. Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake. IJP: Drugs and Drug Resistance, p. 1-9, Fev. 2019.
2211-3207
10.1016/j.ijpddr.2019.02.005
Autor
Espada, Caroline Ricce
Magalhães, Rubens M
Cruz, Mario C
Machado, Paulo Roberto
Schriefer, Albert
Carvalho, Edgar Marcelino de
Hornillos, Valentín
Alves, João M.
Cruz, Angela Kaysel
Coelho, Adriano Cappellazzo
Uliana, Silvia Reni Bortolin
Resumen
Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2011/20484-7
and 2015/09080-2) and Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq, 473343/2012-6), Brazil. This study
was financed in part by the Coordenação de Aperfeiçoamento de
Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. SRBU is
the recipient of a senior researcher scholarship from CNPq. ACC and
CRE were fellows supported by FAPESP (2012/14629-5 and 2016/
23405-4). In Brazil, cutaneous leishmaniasis is caused predominantly by L. (V.) braziliensis. The few therapeutic drugs available exhibit several limitations, mainly related to drug toxicity and reduced efficacy in some regions. Miltefosine (MF), the only oral drug available for leishmaniasis treatment, is not widely available and has not yet been approved for human use in Brazil. Our group previously reported the existence of differential susceptibility among L. (V.) braziliensis clinical isolates. In this work, we further characterized three of these isolates of L. (V.) braziliensis chosen because they exhibited the lowest and the highest MF half maximal inhibitory concentrations and were therefore considered less tolerant or more tolerant, respectively. Uptake of MF, and also of phosphocholine, were found to be significantly different in more tolerant parasites compared to the less sensitive isolate, which raised the hypothesis of differences in the MF transport complex Miltefosine Transporter (MT)-Ros3. Although some polymorphisms in those genes were found, they did not correlate with the drug susceptibility phenotype. Drug efflux and compartmentalization were similar in the isolates tested, and amphotericin B susceptibility was retained in MF tolerant parasites, suggesting that increased fitness was also not the basis of observed differences. Transcriptomic analysis revealed that Ros3 mRNA levels were upregulated in the sensitive strain compared to the tolerant ones. Increased mRNA abundance in more tolerant isolates was validated by quantitative PCR. Our results suggest that differential gene expression of the MT transporter complex is the basis of the differential susceptibility in these unselected, naturally occurring parasites.